论文部分内容阅读
目的··:进一步确认氨酚待因Ⅱ号片(安度芬)的镇痛效果、不良反应及其与用药剂量的关系,以便更好地指导临床用药。方法··:采用无对照开放试验进行100例扩大临床验证。通过滴定期内每日剂量的调整,寻找癌症患者24h内不疼或基本不疼的给药方案。结果··:只要用药剂量调整到位,中度疼痛均能完全缓解,未发现明显不良反应。通过调整后的日剂量与用药前的疼痛强度呈正相关;平均日剂量应为6-8片。结论··:再次证实安度芬是一个镇痛效果较强,不良反应较小的镇痛药。可广泛用于中度疼痛和癌症患者的Ⅱ阶梯镇痛。
OBJECTIVE: To further confirm the analgesic effect, adverse reactions and the relationship between the paracetamol and diphenhydramine hydrochloride tablets (Avastin) and its dosage in order to better guide clinical medication. Methods · · ·: use of uncontrolled open trial of 100 cases to expand clinical validation. Through the titration of the daily dose adjustment, looking for cancer patients within 24h pain or basic pain scheme. Results · · · ·: As long as the dose adjustment in place, moderate pain can be completely relieved, no significant adverse reactions were found. By adjusting the daily dose and medication before the pain intensity was positively correlated; the average daily dose should be 6-8 tablets. Conclusions ··: Again confirmed that Andufen is a strong analgesic effect, adverse reactions smaller analgesic. Can be widely used in patients with moderate pain and cancer Ⅱ ladder pain.